Demonstration of the importance of biphasic oleic acid delivery for enhancing the bioavailability of propranolol in healthy volunteers

Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core

The bioavailability of propranolol from a matrix-in-cylinder system for sustained drug delivery, consisting of a hot-melt extruded ethylcellulose pipe surrounding a drug-containing HPMC-Gelucire 44/14 core, was determined. An oral dose of 80 mg propranolol hydrochloride was administered to healthy volunteers (n = 10) in a randomized cross-over study design either as a commercial pellet formulation (Inderal retard mitis) or as a matrix-in-cylinder system. The influence of concomitant food intake on drug release from the matrix-in-cylinder system was also studied. During the first 10 h after administration, the matrix-in-cylinder system resulted in similar plasma levels as the reference formulation Inderal. The concomitant intake of a high-fat, high-calorie breakfast did not cause dose-dumping. Between 10 h and 24 h after administration of the matrix-in-cylinder system, a remarkable increase of the propranolol plasma levels was noticed (compared to Inderal). This effect was even more pronounced under fed conditions. The matrix-in-cylinder system had a relative bioavailability of 156% (fasted conditions) and 222% (fed conditions) compared to the marketed reference product. In order to elucidate the origin of this increased bioavailability, Caco-2 experiments and dog lymph studies were performed. However, none of these experiments was able to provide a conclusive answer.

In vitro and in vivo evaluation of a matrix-in-cylinder system for sustained drug delivery

A matrix-in-cylinder system for sustained drug delivery, consisting of a hot-melt extruded ethylcellulose (EC) pipe surrounding a drug containing HPMC-Gelucire 44/14 core, was evaluated in vitro and in vivo. In an aqueous medium, the HPMC-Gelucire core forms a gel plug, which releases the drug-through the open ends of the EC pipe--by means of erosion. The influence of hydrodynamic and mechanical stress and the effect of different 'physiologically relevant' dissolution media on the in vitro drug release were investigated. From these in vitro dissolution tests, it was concluded that the EC pipe has a protective effect on the drug containing HPMC-Gelucire core. It largely protects the core against hydrodynamics and mechanical stress. Furthermore, drug release from the matrix-in-cylinder system was only slightly affected by the composition of the dissolution medium. A randomised crossover in vivo study in dogs revealed that the matrix-in-cylinder system containing propranolol hydrochloride has an ideal sustained release profile with constant plasma levels maintained over 24 h. Moreover, administration of the matrix-in-cylinder system resulted in a 4-fold increase in propranolol bioavailability when compared with a commercial sustained release formulation (Inderal).

Drug-fatty acid salt with wax-like properties employed as binder in melt granulation

The tacky and deformable properties of a wax-like drug-fatty acid salt, propranolol oleate (POA), make particle size reduction and separation challenging. The aim of this study was to investigate the use of POA as binder in a melt granulation procedure to improve processing properties. POA is a suitable candidate for binder phase in melt granulation with a melting temperature of 50-56 degrees C. Small batches (ca 30 g) were manufactured using a high shear mixer with lactose monohydrate as the substrate phase. Optimum uniformity of drug content and minimum friability were found at 10% w/w POA binder concentration. POA melt granules exhibited a >10-fold increase in the rate of in vitro dissolution at pH 7.4 with 0.2% w/v sodium lauryl sulphate compared with raw POA. The increased drug surface area in granular form was thought to be responsible for the change in dissolution behaviour. This study has demonstrated that melt granulation using POA as binder is a viable process which leads to beneficial changes in dissolution behaviour for the lipophilic drug-fatty acid salt.

Oleate salt formation and mesomorphic behavior in the propranolol/oleic acid binary system

Thermal analysis of propranolol/oleic acid mixtures prepared by solvent evaporation enabled construction of the binary system phase diagram. This allowed both physical and chemical interactions to be identified, including complex formation at the equimolar composition. An incongruent melting complex with a characteristic reaction point was identified in excess oleic acid compositions, a common property of fatty acid/fatty acid salt binary systems. The equimolar complex was confirmed to be propranolol oleate using infrared spectroscopy. Wide-angle X-ray powder diffractometry demonstrated that propranolol oleate possessed long-range positional order ( approximately 25 A d spacing) accompanied by a degree of disorder over shorter d spacings. Such a pattern suggested mesophase formation, explaining the unctuous nature of propranolol oleate at room temperature. Accurate measurement of the long-range d spacing was achieved using small-angle X-ray scattering, permitting differentiation of the three different phases identified (phase I: 25.4 A, phase II: 24.6 A, phase III: 25.4-25.5 A). The implications of drug fatty acid salt formation and also mesomorphism in pharmaceutical systems are discussed.

Recent developments in oral multiphase and targeted release products

This review examines recent approaches to formulation that are aimed at oral multiphase and targeted release products, and comments on their potential for commercial manufacture. In addition, it identifies a trend within current development in the formation of systems that are designed to alter specific absorption processes. This is in contrast to classical routes, which effectively adapt to normal physiological functions. These new approaches may have two major benefits in both facilitating consistent, reliable oral dosing of new complex molecules, such as those discovered within the biotechnology industry, and permitting dosage reduction of current common molecules.